PCSA (Processa Pharmaceuticals) Net Margin %: 0.00% (As of Mar. 2026)


PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.16
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Net Margin %?

Processa Pharmaceuticals PCSA +9.64% 28 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Processa Pharmaceuticals ranks worse than 106496.17% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Processa Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was $-3.38 Mil. Processa Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Processa Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Processa Pharmaceuticals's Net Margin % or its related term are showing as below:


PCSA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Processa Pharmaceuticals  (NAS:PCSA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Processa Pharmaceuticals Net Margin % Related Terms

Processa Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Net Margin % Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Processa Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCSA vs ELAB, MBIO, DRMA: Net Margin % Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Net Margin % falls into.


PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Processa Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-13.564/0
= %

Processa Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.377/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Processa Pharmaceuticals (PCSA) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry.
Is Processa Pharmaceuticals' Net Margin % too high?
Processa Pharmaceuticals' current Net Margin % is 0.00%. Based on the distribution chart, Processa Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Net Margin % compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #999999 out of 939 companies for Net Margin %. This places Processa Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price